Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant for Acute Treatment of Migraine in Children and Adolescents
NCT04649242Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jan 2021
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of rimegepant in migraine, sponsored by Pfizer. Started Jan 2021; status: recruiting.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04649242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04649242.